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Dear Prof Wahab,  
 
Your manuscript entitled "Potential New H1N1 Neuraminidase Inhibitors from 
Ferulic Acid and Vanillin: Molecular Modelling, Synthesis and in Vitro Assay" 
has now been reviewed and the reviewer comments are appended below. You 
will see that, while they find your work of interest, they have raised points that 
need to be addressed by a major revision.  
 
We therefore invite you to revise and resubmit your manuscript, taking into 
account the points raised. At the same time, we ask that you ensure your 
manuscript complies with our format requirements explained in full at 
http://www.nature.com/srep/authors/submit.html.  
 
Please use the following link to submit a revised paper and a point-by-point 
response to the referees:  
Link Not Available  
** This url links to your confidential homepage and associated information about 
manuscripts you may have submitted or be reviewing for us. If you wish to 
forward this email to co-authors, please delete the link to your homepage first **  
 
We hope to receive your revised paper within four weeks. If you cannot send it 
within this time, please let us know so that we can close your file. In this event, 
we will still be happy to reconsider your paper at a later date as long as you 
haven’t submitted similar or related work elsewhere in the meantime.  
 
NPG offers an open access support service to make it easier for our authors to 
discover and apply for APC funding. For further information please visit 
http://www.nature.com/authors/open_access/funding.html  
 
We look forward to hearing from you soon.  
 
Best regards,  
 
Cheryl Ingram-Smith  
Editorial Board Member  
Scientific Reports  
 
Reviewer comments:  
 
Reviewer #1 (Technical Comments to the Author):  
 
There is unfortunately an apparent disconnection between the enzymatic 
activities/neuraminidase (moderate, high micromolar) and the antiviral activities 
in the antiviral assay (low micro/sub micro values). The authors should try to 
ascertain what is the MoA of the compounds, as probably it won't be related to 
Neuraminidase inhibition.  
 
Other than that, the article is well written, and the reported structures would be of 
interest for the scientific community.  
 
Reviewer #1 (Remarks to the Author):  
 
There is unfortunately an apparent disconnection between the enzymatic 
activities/neuraminidase (moderate, high micromolar) and the antiviral activities 
in the antiviral assay (low micro/sub micro values). The authors should try to 
ascertain what is the MoA of the compounds, as probably it won't be related to 
Neuraminidase inhibition; as such, the conclusions are too generic/unspecific.  
 
 
Reviewer #2 (Remarks to the Author):  
 
Comments and questions to authors  
In this work, neuraminidase inhibitors have been designed and tested against 
influenza virus subtype H1N1 using in silico and in vitro techniques. The authors 
found that some ferulic acid (FA) and vanillin (VN) derivatives might possibly 
use as guideline and/or starting template for further drug development. This 
manuscript could be published after revision according to the comments and 
suggestion as follow;  
1. In introduction part, authors described about interesting scaffold of FA and its 
planar aromatic. I was wondering about ‘this favorable entropy generally 
increase ligand-receptor binding affinity….’. Please clarify this sentence for 
general readers.  
2. Protein preparation for molecular docking and description how to calculate the 
binding free energy calculation should be added.  
3. The design of FA derivatives is based on the structure of commercial drugs 
OTV, ZNV, etc. (Results of molecular modelling part). Please clarify this point 
for general readers, this part is quite hard to follow.  
4. As the authors determine the IC50 value of each compound, have the authors 
approximated the binding free energy from this value? And is it in consistent 
with that obtained from molecular docking? The calculated and experimental 
binding free energies should be compared and discussed.  
5. As a result of NA-VN docking, it showed that VN bound outside the active 
site, thus it would be better if the authors could deeply examine the source of this 
phenomenon. Since VN molecule is quite small, it would easily embedded in the 
NA active site. In addition, why the binding free energy values of OTV and ZNR 
in pages 6 and 8 are different?  
6. As Page 7 (lines 10-12), the authors mentioned that the hydrogen bonds have 
been formed to stabilize MY7 and MY8 in Fig. 4. Both ligands also formed 
hydrogen bond with E277 (as the authors mentioned); however it seems quite far 
from the side chain of the ligands. These contexts are contrast to themselves. 
Besides, all designed inhibitors lose interaction with R292, one of important 
residues for drug binding.  
7. Chemical structures in Fig. 2 should be presented in the active form. The 
assignment of protonation state is very important. As some derivatives (e.g. 
MY7, MY8, etc.) contained the guanidinium group, same as that of ZNR (Fig. 3), 
however their protonation states are different as shown in Fig. 4. This must be 
carefully checked and corrected.  
8. In page 8, you refer to entropy ‘This might be due to increased in the entropy 
as MY6…’. Since this work does not calculate the entropy change, it should 
avoid this keyword.  
9. Conclusion then should be added.  
10. Language and content must be checked and corrected before publication.  
 
 
Editorial Board Member comments:  
 
Although problems were noted, the reviews are overall favorable. Please read 
and address the reviewers' comments carefully, and indicate how each comment 
was addressed in a point-by-point response.  
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